Atakan Topcu1, H Hakan Mursaloglu2, Yasemin Yalcinkaya3, Sait Karakurt4, Burcu Yagiz5, Zeynep Alaca1, Meryem Demir1, Belkis Nihan Coskun5, Ediz Dalkilic5, Nevsun Inanc6. 1. Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey. 2. Marmara University School of Medicine, Istanbul, Turkey. 3. Division of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey. 4. Department of Chest Diseases and Intensive Care, Marmara University School of Medicine, Istanbul, Turkey. 5. Division of Rheumatology, Bursa Uludağ University Faculty of Medicine, Bursa, Turkey. 6. Division of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey. inanc.nevsun@gmail.com.
Abstract
OBJECTIVES: We aim to investigate the relationship between pulmonary function and imaging parameters with symptom-related patient-reported outcome measures (PROs). METHOD: We included 65 patients of rheumatoid arthritis (RA) and connective tissue disease (CTD) with and without interstitial lung disease (ILD) into this cross-sectional study. We evaluated the relationship between FVC, DLco, and PROs and compared to HRCT findings. PROs included visual analogue scale for breathing, modified Borg scale, medical research council dyspnea scale, St. George's respiratory questionnaire (SGRQ), Leicester cough questionnaire, and Short Form 36 quality of life (SF-36 QoL). RESULTS: The mean age was 57.4 ± 9.7 and 61.9% (39/65) of patients had an established ILD. In RA-ILD group, SGRQ score was higher (p < 0.001) and SF-36 physical functioning score was lower (p = 0.02) than CTD-ILD group. In RA group, there was a significant correlation between FVC and SF-36 role functioning/physical score (r = 0.724, p = 0.012). In CTD group, SF-36 general health score was correlated with both FVC (r = 0.441, p = 0.045) and DLco (r = 0.485, p = 0.035), and also SF-36 physical functioning score was correlated with FVC (r = 0.441, p = 0.040). PROs were found to be similar between ILD and non-ILD patients. SF-36 QoL total and SGRQ outcomes were worse in non-ILD group. CONCLUSIONS: We concluded that PROs could be used to evaluate health-related quality of life (HRQoL) in RA- or CTD-related ILD. The physical health determinants of HRQoL are measurably worse in RA-ILD patients than in CTD patients. But, PROs may not be very helpful in differentiating patients with cough and/or shortness of breath due to ILD or non-ILD causes in RA/CTD. KEY POINTS: • HRQoL may be affected differently among specific subtypes of ILD. • PROs can be used to evaluate dyspnea and function of patients with RA- or CTD-related ILD but are not distinguished from patients with cough and/or shortness of breath due to non-ILD causes in RA/CTD.
OBJECTIVES: We aim to investigate the relationship between pulmonary function and imaging parameters with symptom-related patient-reported outcome measures (PROs). METHOD: We included 65 patients of rheumatoid arthritis (RA) and connective tissue disease (CTD) with and without interstitial lung disease (ILD) into this cross-sectional study. We evaluated the relationship between FVC, DLco, and PROs and compared to HRCT findings. PROs included visual analogue scale for breathing, modified Borg scale, medical research council dyspnea scale, St. George's respiratory questionnaire (SGRQ), Leicester cough questionnaire, and Short Form 36 quality of life (SF-36 QoL). RESULTS: The mean age was 57.4 ± 9.7 and 61.9% (39/65) of patients had an established ILD. In RA-ILD group, SGRQ score was higher (p < 0.001) and SF-36 physical functioning score was lower (p = 0.02) than CTD-ILD group. In RA group, there was a significant correlation between FVC and SF-36 role functioning/physical score (r = 0.724, p = 0.012). In CTD group, SF-36 general health score was correlated with both FVC (r = 0.441, p = 0.045) and DLco (r = 0.485, p = 0.035), and also SF-36 physical functioning score was correlated with FVC (r = 0.441, p = 0.040). PROs were found to be similar between ILD and non-ILDpatients. SF-36 QoL total and SGRQ outcomes were worse in non-ILD group. CONCLUSIONS: We concluded that PROs could be used to evaluate health-related quality of life (HRQoL) in RA- or CTD-related ILD. The physical health determinants of HRQoL are measurably worse in RA-ILDpatients than in CTDpatients. But, PROs may not be very helpful in differentiating patients with cough and/or shortness of breath due to ILD or non-ILD causes in RA/CTD. KEY POINTS: • HRQoL may be affected differently among specific subtypes of ILD. • PROs can be used to evaluate dyspnea and function of patients with RA- or CTD-related ILD but are not distinguished from patients with cough and/or shortness of breath due to non-ILD causes in RA/CTD.
Authors: Simon L F Walsh; Nicola Sverzellati; Anand Devaraj; Gregory J Keir; Athol U Wells; David M Hansell Journal: Thorax Date: 2013-10-14 Impact factor: 9.139
Authors: Els Vandecasteele; Michel De Pauw; Filip De Keyser; Saskia Decuman; Ellen Deschepper; Yves Piette; Guy Brusselle; Vanessa Smith Journal: Int J Cardiol Date: 2016-03-25 Impact factor: 4.164
Authors: Leona M Dowman; Christine F McDonald; Catherine J Hill; Annemarie L Lee; Kathryn Barker; Claire Boote; Ian Glaspole; Nicole S L Goh; Anne M Southcott; Angela T Burge; Rebecca Gillies; Alicia Martin; Anne E Holland Journal: Thorax Date: 2017-02-17 Impact factor: 9.139
Authors: Nicole S L Goh; Sujal R Desai; Srihari Veeraraghavan; David M Hansell; Susan J Copley; Toby M Maher; Tamera J Corte; Clare R Sander; Jonathan Ratoff; Anand Devaraj; Gracijela Bozovic; Christopher P Denton; Carol M Black; Roland M du Bois; Athol U Wells Journal: Am J Respir Crit Care Med Date: 2008-03-27 Impact factor: 21.405
Authors: Brent W Kinder; Harold R Collard; Laura Koth; David I Daikh; Paul J Wolters; Brett Elicker; Kirk D Jones; Talmadge E King Journal: Am J Respir Crit Care Med Date: 2007-06-07 Impact factor: 21.405